Information Provided By: 
Fly News Breaks for September 12, 2019
SGEN
Sep 12, 2019 | 07:42 EDT
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
